Search
for
Sort by
Research 601–630 of 1000+
- Alopecia universalis treated with simvastatin/ezetimibe, minoxidil, and prednisolone in a 6‐year‐old girl
- Female pattern hair loss, biological ageing and the Leiden Longevity study
- Limited Effectiveness of Platelet-Rich-Plasma Treatment on Chronic Severe Alopecia Areata
- Epigenetic modifications may explain the relative protection of occipital hair follicles from androgenetic alopecia in men
- Oral cyclosporin does not arrest progression of androgenetic alopecia.
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- 75810 Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program
- 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program
- Outcome measure instruments for the assessment and treatment of androgenetic alopecia: A scoping review
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial
- Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross‐Sectional Survey Study
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
- Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
- The most impactful aspects of living with alopecia areata among patients commencing systemic treatments: Evaluating patients’ perspectives to guide therapy
- Supplementary data: Treatment of androgenetic alopecia with sublingual minoxidil in transgender people receiving testosterone
- Minoxidil
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- A multicentre cohort study of the clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution
- 61720 The effect of sublingual minoxidil on androgenetic alopecia in transgender individuals receiving testosterone for gender-affirmation: A 24-week single-centre double-blinded, randomized, placebo-controlled clinical trial
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- You cannot go bald without first, losing your hair: Telogen effluvium is a precursor to, prerequisite for and potentially an incitant to common baldness in men
- Scalp hair repigmentation after radiotherapy
- Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
- COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists